Geron says FDA halts testing of lead drug
(Reuters) - Geron Corp said the U.S. Food and Drug Administration had ordered to halt the trials of its cancer drug imetelstat due to concerns of liver damage.
The company said the FDA verbally notified them about the hold, which will affect all trials of the treatment, including its thrombocythemia and multiple myeloma mid-stage studies.
The experimental blood cancer drug was touted as a saviour for the company in November, after a number of trial patients were cured.
Geron's shares closed at $4.40 on the Nasdaq on Tuesday.
(Reporting by Natalie Grover and Chris Peters in Bangalore; Editing by Gopakumar Warrier)
- Islamic State video purports to show beheading of U.S. journalist |
- Missouri suburb braces for more racial unrest but calm prevails
- 'No' from one Iraq villager triggered Islamic State mass killings |
- Advancing Ukraine troops take fight to heart of pro-Moscow rebellion |
- Islamic State says beheads U.S. journalist, holds another
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video